StreetInsider.com News Articles

StreetInsider.com News Articles http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 12 Jun 2026 16:07:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif StreetInsider.com News Articles http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday Form 8-K SOLIGENIX, INC. For: Jun 10 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++SOLIGENIX%2C+INC.+++++++++++For%3A+Jun+10/26640725.html si-local-file:///var/storage/secattach/20260612/26640725.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++SOLIGENIX%2C+INC.+++++++++++For%3A+Jun+10/26640725.html Fri, 12 Jun 2026 16:07:00 -0400 O.01584314 SNGX Form 8-K SOLIGENIX, INC. For: Jun 10 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++SOLIGENIX%2C+INC.+++++++++++For%3A+Jun+10/26640725.html si-local-file:///var/storage/secattach/20260612/26640725.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++SOLIGENIX%2C+INC.+++++++++++For%3A+Jun+10/26640725.html Fri, 12 Jun 2026 16:07:00 -0400 O.01584314 SNGX Soligenix applies for CEPI funding to develop Bundibugyo Ebola vaccine http://www.streetinsider.com/Corporate+News/Soligenix+applies+for+CEPI+funding+to+develop+Bundibugyo+Ebola+vaccine/26614324.html <p>Soligenix Inc. (NASDAQ: SNGX) announced it will apply for funding from the Coalition for Epidemic Preparedness Innovations to develop a vaccine for Bundibugyo virus, with applications due June 12, 2026.</p><p>The Princeton, New Jersey-based biopharmaceutical company will collaborate with Dr. Axel Lehrer from the University of Hawaii at Manoa on the application. The team previously developed bivalent and trivalent thermostable vaccines against Ebola virus, Sudan virus and Marburg virus using the CoVaccine HT adjuvant.</p><p>According to the press release, these vaccines demonstrated thermostability, immunogenicity and efficacy in non-human primates. The vaccines showed up to 100% protection in non-human primates and maintained stability http://www.streetinsider.com/Corporate+News/Soligenix+applies+for+CEPI+funding+to+develop+Bundibugyo+Ebola+vaccine/26614324.html Mon, 08 Jun 2026 07:31:15 -0400 SNGX Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine http://www.streetinsider.com/Press+Releases/Soligenix+Applying+for+Vaccine+Development+Funding+for+Bundibugyo+Ebola+Vaccine/26614309.html <div class="xn-content"> <p class="prntac"><b><i>Thermostability, immunogenicity and efficacy data against related viruses provides firm starting point for rapid vaccine development</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>June 8, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4705749-1&h=4154964116&u=https%3A%2F%2Fwww.soligenix.com%2F&a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today that the <span value="ACORN:6001200364" idsrc="xmltag.org" >Coalition for Epidemic Preparedness Innovations</span> (CEPI) has announced a call for proposal for vaccine development for Bundibugyo virus (BDBV) with applications due <chron>June 12, 2026</chron>. <span http://www.streetinsider.com/Press+Releases/Soligenix+Applying+for+Vaccine+Development+Funding+for+Bundibugyo+Ebola+Vaccine/26614309.html Mon, 08 Jun 2026 07:30:00 -0400 A.14320728 A.17568957 A.60012003 O.01584314 O.04889877 O.20250741 O.59470868 SNGX Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine http://www.streetinsider.com/Press+Releases/Soligenix+Applying+for+Vaccine+Development+Funding+for+Bundibugyo+Ebola+Vaccine/26614309.html <div class="xn-content"> <p class="prntac"><b><i>Thermostability, immunogenicity and efficacy data against related viruses provides firm starting point for rapid vaccine development</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>June 8, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4705749-1&h=4154964116&u=https%3A%2F%2Fwww.soligenix.com%2F&a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today that the <span value="ACORN:6001200364" idsrc="xmltag.org" >Coalition for Epidemic Preparedness Innovations</span> (CEPI) has announced a call for proposal for vaccine development for Bundibugyo virus (BDBV) with applications due <chron>June 12, 2026</chron>. <span http://www.streetinsider.com/Press+Releases/Soligenix+Applying+for+Vaccine+Development+Funding+for+Bundibugyo+Ebola+Vaccine/26614309.html Mon, 08 Jun 2026 07:30:00 -0400 A.14320728 A.17568957 A.60012003 O.01584314 O.04889877 O.20250741 O.59470868 SNGX Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine http://www.streetinsider.com/Press+Releases/Soligenix+Applying+for+Vaccine+Development+Funding+for+Bundibugyo+Ebola+Vaccine/26614309.html <div class="xn-content"> <p class="prntac"><b><i>Thermostability, immunogenicity and efficacy data against related viruses provides firm starting point for rapid vaccine development</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>June 8, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4705749-1&h=4154964116&u=https%3A%2F%2Fwww.soligenix.com%2F&a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today that the <span value="ACORN:6001200364" idsrc="xmltag.org" >Coalition for Epidemic Preparedness Innovations</span> (CEPI) has announced a call for proposal for vaccine development for Bundibugyo virus (BDBV) with applications due <chron>June 12, 2026</chron>. <span http://www.streetinsider.com/Press+Releases/Soligenix+Applying+for+Vaccine+Development+Funding+for+Bundibugyo+Ebola+Vaccine/26614309.html Mon, 08 Jun 2026 07:30:00 -0400 A.14320728 A.17568957 A.60012003 O.01584314 O.04889877 O.20250741 O.59470868 SNGX Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine http://www.streetinsider.com/Press+Releases/Soligenix+Applying+for+Vaccine+Development+Funding+for+Bundibugyo+Ebola+Vaccine/26614309.html <div class="xn-content"> <p class="prntac"><b><i>Thermostability, immunogenicity and efficacy data against related viruses provides firm starting point for rapid vaccine development</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>June 8, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4705749-1&h=4154964116&u=https%3A%2F%2Fwww.soligenix.com%2F&a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today that the <span value="ACORN:6001200364" idsrc="xmltag.org" >Coalition for Epidemic Preparedness Innovations</span> (CEPI) has announced a call for proposal for vaccine development for Bundibugyo virus (BDBV) with applications due <chron>June 12, 2026</chron>. <span http://www.streetinsider.com/Press+Releases/Soligenix+Applying+for+Vaccine+Development+Funding+for+Bundibugyo+Ebola+Vaccine/26614309.html Mon, 08 Jun 2026 07:30:00 -0400 A.14320728 A.17568957 A.60012003 O.01584314 O.04889877 O.20250741 O.59470868 SNGX Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine http://www.streetinsider.com/Press+Releases/Soligenix+Applying+for+Vaccine+Development+Funding+for+Bundibugyo+Ebola+Vaccine/26614309.html <div class="xn-content"> <p class="prntac"><b><i>Thermostability, immunogenicity and efficacy data against related viruses provides firm starting point for rapid vaccine development</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>June 8, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4705749-1&h=4154964116&u=https%3A%2F%2Fwww.soligenix.com%2F&a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today that the <span value="ACORN:6001200364" idsrc="xmltag.org" >Coalition for Epidemic Preparedness Innovations</span> (CEPI) has announced a call for proposal for vaccine development for Bundibugyo virus (BDBV) with applications due <chron>June 12, 2026</chron>. <span http://www.streetinsider.com/Press+Releases/Soligenix+Applying+for+Vaccine+Development+Funding+for+Bundibugyo+Ebola+Vaccine/26614309.html Mon, 08 Jun 2026 07:30:00 -0400 A.14320728 A.17568957 A.60012003 O.01584314 O.04889877 O.20250741 O.59470868 SNGX Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine http://www.streetinsider.com/Press+Releases/Soligenix+Applying+for+Vaccine+Development+Funding+for+Bundibugyo+Ebola+Vaccine/26614309.html <div class="xn-content"> <p class="prntac"><b><i>Thermostability, immunogenicity and efficacy data against related viruses provides firm starting point for rapid vaccine development</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>June 8, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4705749-1&h=4154964116&u=https%3A%2F%2Fwww.soligenix.com%2F&a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today that the <span value="ACORN:6001200364" idsrc="xmltag.org" >Coalition for Epidemic Preparedness Innovations</span> (CEPI) has announced a call for proposal for vaccine development for Bundibugyo virus (BDBV) with applications due <chron>June 12, 2026</chron>. <span http://www.streetinsider.com/Press+Releases/Soligenix+Applying+for+Vaccine+Development+Funding+for+Bundibugyo+Ebola+Vaccine/26614309.html Mon, 08 Jun 2026 07:30:00 -0400 A.14320728 A.17568957 A.60012003 O.01584314 O.04889877 O.20250741 O.59470868 SNGX Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine http://www.streetinsider.com/Press+Releases/Soligenix+Applying+for+Vaccine+Development+Funding+for+Bundibugyo+Ebola+Vaccine/26614309.html <div class="xn-content"> <p class="prntac"><b><i>Thermostability, immunogenicity and efficacy data against related viruses provides firm starting point for rapid vaccine development</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>June 8, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4705749-1&h=4154964116&u=https%3A%2F%2Fwww.soligenix.com%2F&a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today that the <span value="ACORN:6001200364" idsrc="xmltag.org" >Coalition for Epidemic Preparedness Innovations</span> (CEPI) has announced a call for proposal for vaccine development for Bundibugyo virus (BDBV) with applications due <chron>June 12, 2026</chron>. <span http://www.streetinsider.com/Press+Releases/Soligenix+Applying+for+Vaccine+Development+Funding+for+Bundibugyo+Ebola+Vaccine/26614309.html Mon, 08 Jun 2026 07:30:00 -0400 A.14320728 A.17568957 A.60012003 O.01584314 O.04889877 O.20250741 O.59470868 SNGX Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine http://www.streetinsider.com/Press+Releases/Soligenix+Applying+for+Vaccine+Development+Funding+for+Bundibugyo+Ebola+Vaccine/26614309.html <div class="xn-content"> <p class="prntac"><b><i>Thermostability, immunogenicity and efficacy data against related viruses provides firm starting point for rapid vaccine development</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>June 8, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4705749-1&h=4154964116&u=https%3A%2F%2Fwww.soligenix.com%2F&a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today that the <span value="ACORN:6001200364" idsrc="xmltag.org" >Coalition for Epidemic Preparedness Innovations</span> (CEPI) has announced a call for proposal for vaccine development for Bundibugyo virus (BDBV) with applications due <chron>June 12, 2026</chron>. <span http://www.streetinsider.com/Press+Releases/Soligenix+Applying+for+Vaccine+Development+Funding+for+Bundibugyo+Ebola+Vaccine/26614309.html Mon, 08 Jun 2026 07:30:00 -0400 A.14320728 A.17568957 A.60012003 O.01584314 O.04889877 O.20250741 O.59470868 SNGX Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine http://www.streetinsider.com/PRNewswire/Soligenix+Applying+for+Vaccine+Development+Funding+for+Bundibugyo+Ebola+Vaccine/26614309.html <div class="xn-content"> <p class="prntac"><b><i>Thermostability, immunogenicity and efficacy data against related viruses provides firm starting point for rapid vaccine development</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>June 8, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4705749-1&h=4154964116&u=https%3A%2F%2Fwww.soligenix.com%2F&a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today that the <span value="ACORN:6001200364" idsrc="xmltag.org" >Coalition for Epidemic Preparedness Innovations</span> (CEPI) has announced a call for proposal for vaccine development for Bundibugyo virus (BDBV) with applications due <chron>June 12, 2026</chron>. <span http://www.streetinsider.com/PRNewswire/Soligenix+Applying+for+Vaccine+Development+Funding+for+Bundibugyo+Ebola+Vaccine/26614309.html Mon, 08 Jun 2026 07:30:00 -0400 A.14320728 A.17568957 A.60012003 O.01584314 O.04889877 O.20250741 O.59470868 SNGX Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine http://www.streetinsider.com/PRNewswire/Soligenix+Applying+for+Vaccine+Development+Funding+for+Bundibugyo+Ebola+Vaccine/26614309.html <div class="xn-content"> <p class="prntac"><b><i>Thermostability, immunogenicity and efficacy data against related viruses provides firm starting point for rapid vaccine development</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>June 8, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4705749-1&h=4154964116&u=https%3A%2F%2Fwww.soligenix.com%2F&a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today that the <span value="ACORN:6001200364" idsrc="xmltag.org" >Coalition for Epidemic Preparedness Innovations</span> (CEPI) has announced a call for proposal for vaccine development for Bundibugyo virus (BDBV) with applications due <chron>June 12, 2026</chron>. <span http://www.streetinsider.com/PRNewswire/Soligenix+Applying+for+Vaccine+Development+Funding+for+Bundibugyo+Ebola+Vaccine/26614309.html Mon, 08 Jun 2026 07:30:00 -0400 A.14320728 A.17568957 A.60012003 O.01584314 O.04889877 O.20250741 O.59470868 SNGX Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine http://www.streetinsider.com/PRNewswire/Soligenix+Applying+for+Vaccine+Development+Funding+for+Bundibugyo+Ebola+Vaccine/26614309.html <div class="xn-content"> <p class="prntac"><b><i>Thermostability, immunogenicity and efficacy data against related viruses provides firm starting point for rapid vaccine development</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>June 8, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4705749-1&h=4154964116&u=https%3A%2F%2Fwww.soligenix.com%2F&a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today that the <span value="ACORN:6001200364" idsrc="xmltag.org" >Coalition for Epidemic Preparedness Innovations</span> (CEPI) has announced a call for proposal for vaccine development for Bundibugyo virus (BDBV) with applications due <chron>June 12, 2026</chron>. <span http://www.streetinsider.com/PRNewswire/Soligenix+Applying+for+Vaccine+Development+Funding+for+Bundibugyo+Ebola+Vaccine/26614309.html Mon, 08 Jun 2026 07:30:00 -0400 A.14320728 A.17568957 A.60012003 O.01584314 O.04889877 O.20250741 O.59470868 SNGX Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine http://www.streetinsider.com/PRNewswire/Soligenix+Applying+for+Vaccine+Development+Funding+for+Bundibugyo+Ebola+Vaccine/26614309.html <div class="xn-content"> <p class="prntac"><b><i>Thermostability, immunogenicity and efficacy data against related viruses provides firm starting point for rapid vaccine development</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>June 8, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4705749-1&h=4154964116&u=https%3A%2F%2Fwww.soligenix.com%2F&a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today that the <span value="ACORN:6001200364" idsrc="xmltag.org" >Coalition for Epidemic Preparedness Innovations</span> (CEPI) has announced a call for proposal for vaccine development for Bundibugyo virus (BDBV) with applications due <chron>June 12, 2026</chron>. <span http://www.streetinsider.com/PRNewswire/Soligenix+Applying+for+Vaccine+Development+Funding+for+Bundibugyo+Ebola+Vaccine/26614309.html Mon, 08 Jun 2026 07:30:00 -0400 A.14320728 A.17568957 A.60012003 O.01584314 O.04889877 O.20250741 O.59470868 SNGX Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine http://www.streetinsider.com/PRNewswire/Soligenix+Applying+for+Vaccine+Development+Funding+for+Bundibugyo+Ebola+Vaccine/26614309.html <div class="xn-content"> <p class="prntac"><b><i>Thermostability, immunogenicity and efficacy data against related viruses provides firm starting point for rapid vaccine development</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>June 8, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4705749-1&h=4154964116&u=https%3A%2F%2Fwww.soligenix.com%2F&a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today that the <span value="ACORN:6001200364" idsrc="xmltag.org" >Coalition for Epidemic Preparedness Innovations</span> (CEPI) has announced a call for proposal for vaccine development for Bundibugyo virus (BDBV) with applications due <chron>June 12, 2026</chron>. <span http://www.streetinsider.com/PRNewswire/Soligenix+Applying+for+Vaccine+Development+Funding+for+Bundibugyo+Ebola+Vaccine/26614309.html Mon, 08 Jun 2026 07:30:00 -0400 A.14320728 A.17568957 A.60012003 O.01584314 O.04889877 O.20250741 O.59470868 SNGX Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine http://www.streetinsider.com/PRNewswire/Soligenix+Applying+for+Vaccine+Development+Funding+for+Bundibugyo+Ebola+Vaccine/26614309.html <div class="xn-content"> <p class="prntac"><b><i>Thermostability, immunogenicity and efficacy data against related viruses provides firm starting point for rapid vaccine development</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>June 8, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4705749-1&h=4154964116&u=https%3A%2F%2Fwww.soligenix.com%2F&a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today that the <span value="ACORN:6001200364" idsrc="xmltag.org" >Coalition for Epidemic Preparedness Innovations</span> (CEPI) has announced a call for proposal for vaccine development for Bundibugyo virus (BDBV) with applications due <chron>June 12, 2026</chron>. <span http://www.streetinsider.com/PRNewswire/Soligenix+Applying+for+Vaccine+Development+Funding+for+Bundibugyo+Ebola+Vaccine/26614309.html Mon, 08 Jun 2026 07:30:00 -0400 A.14320728 A.17568957 A.60012003 O.01584314 O.04889877 O.20250741 O.59470868 SNGX Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine http://www.streetinsider.com/PRNewswire/Soligenix+Applying+for+Vaccine+Development+Funding+for+Bundibugyo+Ebola+Vaccine/26614309.html <div class="xn-content"> <p class="prntac"><b><i>Thermostability, immunogenicity and efficacy data against related viruses provides firm starting point for rapid vaccine development</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>June 8, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4705749-1&h=4154964116&u=https%3A%2F%2Fwww.soligenix.com%2F&a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today that the <span value="ACORN:6001200364" idsrc="xmltag.org" >Coalition for Epidemic Preparedness Innovations</span> (CEPI) has announced a call for proposal for vaccine development for Bundibugyo virus (BDBV) with applications due <chron>June 12, 2026</chron>. <span http://www.streetinsider.com/PRNewswire/Soligenix+Applying+for+Vaccine+Development+Funding+for+Bundibugyo+Ebola+Vaccine/26614309.html Mon, 08 Jun 2026 07:30:00 -0400 A.14320728 A.17568957 A.60012003 O.01584314 O.04889877 O.20250741 O.59470868 SNGX Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine http://www.streetinsider.com/PRNewswire/Soligenix+Applying+for+Vaccine+Development+Funding+for+Bundibugyo+Ebola+Vaccine/26614309.html <div class="xn-content"> <p class="prntac"><b><i>Thermostability, immunogenicity and efficacy data against related viruses provides firm starting point for rapid vaccine development</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>June 8, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4705749-1&h=4154964116&u=https%3A%2F%2Fwww.soligenix.com%2F&a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today that the <span value="ACORN:6001200364" idsrc="xmltag.org" >Coalition for Epidemic Preparedness Innovations</span> (CEPI) has announced a call for proposal for vaccine development for Bundibugyo virus (BDBV) with applications due <chron>June 12, 2026</chron>. <span http://www.streetinsider.com/PRNewswire/Soligenix+Applying+for+Vaccine+Development+Funding+for+Bundibugyo+Ebola+Vaccine/26614309.html Mon, 08 Jun 2026 07:30:00 -0400 A.14320728 A.17568957 A.60012003 O.01584314 O.04889877 O.20250741 O.59470868 SNGX Form 8-K SOLIGENIX, INC. For: May 28 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++SOLIGENIX%2C+INC.+++++++++++For%3A+May+28/26568921.html si-local-file:///var/storage/secattach/20260528/26568921.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++SOLIGENIX%2C+INC.+++++++++++For%3A+May+28/26568921.html Thu, 28 May 2026 17:21:00 -0400 O.01584314 SNGX Form 8-K SOLIGENIX, INC. For: May 28 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++SOLIGENIX%2C+INC.+++++++++++For%3A+May+28/26568921.html si-local-file:///var/storage/secattach/20260528/26568921.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++SOLIGENIX%2C+INC.+++++++++++For%3A+May+28/26568921.html Thu, 28 May 2026 17:21:00 -0400 O.01584314 SNGX Form 424B5 SOLIGENIX, INC. http://www.streetinsider.com/SEC+Filings/Form++424B5++++++SOLIGENIX%2C+INC.++++++++++++++++++++++/26568913.html si-local-file:///var/storage/secattach/20260528/26568913.html http://www.streetinsider.com/SEC+Filings/Form++424B5++++++SOLIGENIX%2C+INC.++++++++++++++++++++++/26568913.html Thu, 28 May 2026 17:20:00 -0400 O.01584314 SNGX Form 424B5 SOLIGENIX, INC. http://www.streetinsider.com/SEC+Filings/Form++424B5++++++SOLIGENIX%2C+INC.++++++++++++++++++++++/26568913.html si-local-file:///var/storage/secattach/20260528/26568913.html http://www.streetinsider.com/SEC+Filings/Form++424B5++++++SOLIGENIX%2C+INC.++++++++++++++++++++++/26568913.html Thu, 28 May 2026 17:20:00 -0400 O.01584314 SNGX Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo http://www.streetinsider.com/Press+Releases/Suitability+of+Vaccine+Platform+for+Bundibugyo+Virus%2C+Cause+of+the+Ebola+Outbreak+in+Congo/26545899.html <div class="xn-content"> <p class="prntac"><b><i>Thermostability, immunogenicity and efficacy data against related viruses<br />may provide rapid starting point for vaccine development</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>May 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4695242-1&h=3664158382&u=http%3A%2F%2Fwww.soligenix.com%2F&a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today that the recent Congo outbreak of Bundibugyo virus, an <i>Orthoebolavirus</i>, will require new vaccine formulation efforts. <span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span>, in collaboration with <person>Axel Lehrer</person>, PhD, Professor at the <span>Department http://www.streetinsider.com/Press+Releases/Suitability+of+Vaccine+Platform+for+Bundibugyo+Virus%2C+Cause+of+the+Ebola+Outbreak+in+Congo/26545899.html Tue, 26 May 2026 07:30:00 -0400 A.01316444 A.13092795 A.13522767 A.14320728 A.17568957 A.29922014 A.60012002 O.00651740 O.01584314 O.03289173 O.03297629 O.04889877 O.20250741 O.42081221 O.69857460 SNGX Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo http://www.streetinsider.com/Press+Releases/Suitability+of+Vaccine+Platform+for+Bundibugyo+Virus%2C+Cause+of+the+Ebola+Outbreak+in+Congo/26545899.html <div class="xn-content"> <p class="prntac"><b><i>Thermostability, immunogenicity and efficacy data against related viruses<br />may provide rapid starting point for vaccine development</i></b></p><p><span class="legendSpanClass"><location value="LU/us.nj.prnctn" idsrc="xmltag.org" >PRINCETON, N.J.</location></span>, <span class="legendSpanClass"><chron>May 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&l=en&o=4695242-1&h=3664158382&u=http%3A%2F%2Fwww.soligenix.com%2F&a=Soligenix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix, Inc.</span></a> (Nasdaq: SNGX) (<span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span> or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted today that the recent Congo outbreak of Bundibugyo virus, an <i>Orthoebolavirus</i>, will require new vaccine formulation efforts. <span value="NASDAQ-SMALL:SNGX" idsrc="xmltag.org" >Soligenix</span>, in collaboration with <person>Axel Lehrer</person>, PhD, Professor at the <span>Department http://www.streetinsider.com/Press+Releases/Suitability+of+Vaccine+Platform+for+Bundibugyo+Virus%2C+Cause+of+the+Ebola+Outbreak+in+Congo/26545899.html Tue, 26 May 2026 07:30:00 -0400 A.01316444 A.13092795 A.13522767 A.14320728 A.17568957 A.29922014 A.60012002 O.00651740 O.01584314 O.03289173 O.03297629 O.04889877 O.20250741 O.42081221 O.69857460 SNGX